Upside Seen For Celltech From Clinical Progress

2 June 1996

UK company Celltech continues to assert its position as a leader in the emerging biotechnology sector, according to analysts Duncan Moore and Eric Hecht at Morgan Stanley. Noting that Celltech announced total six-month revenues from biologicals of L9.5 million ($14.4 million), up 30%, and L100,000 from ReoPro royalties (Marketletter May 20), the analysts say that the investment community is not critically focussed on financials at this stage of the biotechnology company's development.

However, they have slightly raised their share price target to reflect the clinical progress of Celltech's leukemia drug, a colcheamicin-linked monoclonal antibody in codevelopment with American Home Products, and the positive price guidance on the septic-shock product BAYX-1351, licensed for the UK, Ireland and France from Bayer, which is currently L2,000 per treatment versus the analysts' estimate of L1,300).

Celltech expects to treat around 20,000 patients a year, which equates to a L40 million market. As a result, they add, the share price target has been raised from 650 pence to 750 pence per share.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight